Medicines News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.01.20	Novartis Completes Tender Offer For Medicines Co. (RTTNews)
05.12.19	Novartis Commences Tender Offer For Medicines Company (RTTNews)
26.11.19	Today's Top 5 Gainers In Healthcare Sector (SRNE, MDCO, RAPT...) (RTTNews)
25.11.19	Novartis To Buy Medicines Co. In $9.7 Bln Deal (RTTNews)
24.11.19	The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion (Businesswire)
19.11.19	KRTX Makes Giant Leap, The Medicines' Working Well, AGRX On The Move (RTTNews)
18.11.19	The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing (Businesswire)
16.11.19	The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing (Businesswire)
06.11.19	The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019 (Businesswire)
30.10.19	The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran (Businesswire)
24.10.19	The Medicines Company to Announce Third Quarter 2019 Financial Results on October 30 (Businesswire)
17.10.19	Healthcare Stocks That Hit New Highs(MLSS, MDCO, CBPO...) (RTTNews)
04.10.19	The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference (Businesswire)
25.09.19	The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients (Businesswire)
25.09.19	The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients (Businesswire)
02.09.19	The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing (Businesswire)
26.08.19	The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran (Businesswire)
24.07.19	The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program (Businesswire)
17.07.19	The Medicines Company to Announce Second Quarter 2019 Financial Results on July 24 (Businesswire)
26.06.19	The Medicines Company Announces Pricing of Public Offering of Common Stock (Businesswire)
24.06.19	The Medicines Company Announces Launch of Public Offering of Common Stock (Businesswire)
27.05.19	The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress (Businesswire)
18.05.19	New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years (Businesswire)
10.05.19	The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association’s 2019 Scientific Sessions (Businesswire)
25.04.19	The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program (Businesswire)
18.04.19	The Medicines Company to Announce First Quarter 2019 Financial Results on April 25 (Businesswire)
21.02.19	The Medicines Company Announces Upcoming Investor Conference Presentations (Businesswire)
20.02.19	The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27 (Businesswire)
07.01.19	The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials (Businesswire)
21.12.18	FDA Nod For GNMK, AKRX Gets New CEO, PTI Plunges After-hours (RTTNews)
14.12.18	The Medicines Company Prices $150 Million of Convertible Notes (Businesswire)
13.12.18	GLMD On Watch, ARDS On The Move, MDCO Gets New CEO (RTTNews)
11.12.18	The Medicines Company Appoints Mark Timney as Chief Executive Officer (Businesswire)
09.11.18	Company Profile for The Medicines Company (Businesswire)
08.11.18	The Medicines Company Reports Third-Quarter 2018 Results (Businesswire)
01.11.18	The Medicines Company to Announce Third-Quarter 2018 Financial Results on November 8 (Businesswire)
01.08.18	The Medicines Company Reports Second-Quarter 2018 Results (Businesswire)
26.07.18	The Medicines Company to Announce Second-Quarter 2018 Financial Results on August 1 (Businesswire)
27.06.18	The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded Data (Businesswire)
26.06.18	New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes (Businesswire)
07.05.18	The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke (Businesswire)
30.04.18	The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions (Businesswire)
25.04.18	The Medicines Company Reports First-Quarter 2018 Results (Businesswire)
19.04.18	The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25 (Businesswire)
09.03.18	FDA Panel Backs Xeljanz For UC, ACRX Abuzz, AGLE Awaits Data This Month (RTTNews)
23.01.18	ARRY Shines A BEACON, So Long To JUNO And BIVV, Exciting Time Ahead For GEMP (RTTNews)
08.01.18	Sanofi And Alnylam Restructure RNAi Therapeutics Rare Disease Alliance (RTTNews)
29.11.17	Medicines Co. To Sell Infectious Disease Business Unit To Melinta Therapeutics (RTTNews)
29.11.17	Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines... (PR Newswire)
06.11.17	Medicines Co., Alnylam Pharma Initiate Phase III Clinical Trial Of Inclisiran (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

25.11.19		Novartis-Aktie leicht im Plus, Medicines-Aktie springt an: Novartis wohl mit Medicines einig über Milliarden-Kauf
19.11.19		Medicines Co-Aktie +20%: Novartis angeblich an Medicines Co. interessiert

25.11.19

Novartis-Aktie leicht im Plus, Medicines-Aktie springt an: Novartis wohl mit Medicines einig über Milliarden-Kauf

19.11.19

Medicines Co-Aktie +20%: Novartis angeblich an Medicines Co. interessiert

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Medicines Co.

Aktien Top/Flop

Medicines Peer Group Nachrichten

Meistgelesene Nachrichten